ASXL1 and myeloproliferative disorder: Over the last decade, the mechanisms of action of MPN-driving mutations, as well as co-occurring mutations (ASXL1, EZH2, DNMT3A, TET2), in MPN disease initiation and progression have been extensively studied, in vitro and in murine models (21–30).